GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,392.50p
   
  • Change Today:
    -14.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,372.50p
  • Currency: UK Pounds
  • Shares Issued: 4,145.09m
  • Volume: 15,719,161
  • Market Cap: £57,720m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart (31-10-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.9% 0.0%
Div Cover n/a 2.6
Op Mrgn n/a 26.7%
ROCE n/a  
Latest F'cast
P/E 39.6 9.3
PEG n/a 41.2
Pr/Revenue 9.6 1.9
Pr/Book 5.3  
Latest F'cast
Revenue n/a 326.4%
PBT 7.7% 518.9%
EPS n/a -0.1%
DPS n/a 301.2%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 33,754.00 6,221.00 123.90p 17.9 4.5 +4% 80.00p 3.6%
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 42.00p 2.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 31,395.70 8,385.96 154.94p 9.0 n/a -0% 60.18p 0.0%
31-Dec-25 32,947.95 9,340.88 171.87p 8.1 0.7 +11% 63.67p 0.0%
31-Dec-26 34,784.02 10,387.80 190.26p 7.3 0.7 +11% 68.02p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Director/PDMR Shareholding 30-Oct-2024 14:29 RNS
3rd Quarter Results 30-Oct-2024 07:00 RNS
New positive Arexvy data in younger adults at risk 24-Oct-2024 07:00 RNS

GSK ShareCast News

London close: Stocks mixed as Chancellor unveils... 30-Oct-2024 ShareCast
GSK maintains guidance after mixed third quarter 30-Oct-2024 ShareCast
GSK RSV vaccine shows potential to help protect ... 24-Oct-2024 ShareCast

GSK Top Newspaper Links

GSK offsets vaccine losses with new drugs for ca... 30-Oct-2024 Times
GSK under pressure over key vaccines 28-Oct-2024 Times
GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
30-Oct-24 Buy Jonathan Symonds 1,393.65p 7,150 £99,645.97
15-Oct-24 Buy Dividends Julie Brown 1,505.00p 571 £8,593.55
15-Oct-24 Buy Dividends Hal Barron 2,999.40p 431 £12,927.43

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,392.50p
Change Today -14.50p
% Change -1.03 %
52 Week High 1,812.50p
52 Week Low 1,372.50p
Volume 15,719,161
Shares Issued 4,145.09m
Market Cap £57,720m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
59.59% below the market average59.59% below the market average59.59% below the market average59.59% below the market average59.59% below the market average
16% below the sector average16% below the sector average16% below the sector average16% below the sector average16% below the sector average
Price Trend
38.77% below the market average38.77% below the market average38.77% below the market average38.77% below the market average38.77% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Income
38.96% above the market average38.96% above the market average38.96% above the market average38.96% above the market average38.96% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
4.69% below the market average4.69% below the market average4.69% below the market average4.69% below the market average4.69% below the market average
29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average

What The Brokers Say

Strong Buy 8
Buy 4
Neutral 10
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 15-Nov-24 15-Aug-24
Paid 09-Jan-25 10-Oct-24
Amount 15.00p 15.00p

Trades for 31-Oct-2024

Time Volume / Share Price
16:08 1,933,405 @ 1,396.50p
17:00 34,816 @ 1,393.51p
17:00 34,816 @ 1,393.09p
16:39 23,796 @ 1,392.50p
16:39 44,986 @ 1,392.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page